Takeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week for its first-in-class orexin agonist for treating narcolepsy type 1

Christophe Weber discusses the 25 year journey from the discovery that orexin deficiency is the cause of narcolepsy to announcing two positive phase three studies with an agonist. He shares highlights of the World Sleep Congress data, and how he views emerging competitors in the class.